路透9月1日消息——欧康维视生物（股票代码：1477.HK）今日宣布，其地塞米松眼内悬浊液的新药上市申请，已正式获得中国国家药品监督管理局（NMPA）受理，该申请被归类为4类化学药品。此次受理标志着公司在眼科治疗领域的又一重要进展。
路透9月1日消息——欧康维视生物（股票代码：1477.HK）今日宣布，其地塞米松眼内悬浊液的新药上市申请，已正式获得中国国家药品监督管理局（NMPA）受理，该申请被归类为4类化学药品。此次受理标志着公司在眼科治疗领域的又一重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.